Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
Accessing Metabolic Information with Mass Spec
Scientists at the Helmholtz Zentrum München have developed a new mass spectrometry imaging method which, for the first time, makes it possible to analyze hundreds of metabolites in fixed tissue samples.
Simplifying Gene Testing Access for Ovarian Cancer Patients
Simplifying access to gene testing for women with ovarian cancer improves treatment choices and could save lives.
New Protein Model Could Accelerate Drug Development
Stony Brook-led international research team creates ultra-fast approach to model protein interactions.
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Angina Drug Could Inform A New Strategy To Fight Cryptococcosis
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis.
New Skin Cancer Drugs with Surprising Powers
Inserm team synthesizes and developed new drugs for melanoma.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Scroll Up
Scroll Down

Competitive Edge
Bookmark and Share

AMRI

Rising R&D costs, increasing expectations in the areas of productivity and quality, and a growing need to establish operations in close proximity to emerging markets are driving the international expansion of drug-discovery organizations. This global shift is driving new trends in the area of career development and hiring, such as the need for experienced scientific professionals at different locations all over the globe. Although the global pharmaceutical industry is going through significant changes, the role of medicinal chemistry in identifying and optimizing potential new drug candidates remains substantial. Going forward, current and future candidates in the area of medicinal chemistry and other scientific disciplines who have a willingness to work overseas may gain a competitive advantage when entering or advancing within the drug discovery field. 

During the past 10 years, there has been limited growth in the number of approved new chemical entities entering the marketplace in spite of a significant increase in overall R&D spending. For a number of reasons, R&D activities have also become more global during this time. As a result of this globalization associated with expanding international operations, there is an increased need for talent – principally with discovery and development skill sets – that may favor candidates who are willing to consider working in these non-traditional locations. 

Further Information

Related Content

AMRI To Acquire Aptuit Drug Product Development Businesses
Significantly expands AMRI's analytical services capabilities and extends drug product development services to include sterile injectable formulation development.
Friday, January 09, 2015
AMRI Announces Senior Level Leadership Appointment
The appointment of Michael A. Luther, Ph.D. as Senior Vice President of Discovery sees AMRI expanding its biology capabilities.
Thursday, October 17, 2013
AMRI and Ono Broaden SMARTSOURCING™ Collaboration
New agreement extends drug discovery and development collaboration between the companies.
Friday, April 26, 2013
AMRI Further Expands Discovery Capabilities in India
Two strategic hires bring additional flexibility to global drug discovery operations.
Thursday, June 21, 2012
AMRI Signs Exclusive Option to License its Tubulin Inhibitor Program for Cancer
Agreement demonstrates AMRI’s commitment to value creation from its proprietary portfolio of compounds and programs.
Friday, April 06, 2012
Third Compound from AMRI Bristol-Myers Squibb Collaboration Selected for Preclinical Development
AMRI to receive a $750,000 milestone payment from licensing agreement.
Wednesday, November 11, 2009
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!